Irritable Bowel Syndrome Ibs Market Insight Epidemiology And Market Forecast

DelveInsight's 'Irritable Bowel Syndrome (IBS) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of IBS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Irritable Bowel Syndrome (IBS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan


Study Period: 2017-2028

Irritable Bowel Syndrome (IBS) - Disease Understanding and Treatment Algorithm

The DelveInsight Irritable Bowel Syndrome (IBS) market report gives the thorough understanding of the Irritable Bowel Syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Irritable Bowel Syndrome in the US, Europe, and Japan.


Irritable Bowel Syndrome Epidemiology

The Irritable Bowel Syndrome (IBS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, diagnosed prevalent cases by types, severity specific prevalent cases, diagnosed prevalent cases by age groups and prevalent cases based on gender) scenario of Irritable Bowel Syndrome (IBS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Irritable Bowel Syndrome (IBS) in 7 MM was found to be 101,582,018, in the year 2017.


Irritable Bowel Syndrome Drug Chapters

This segment of the Irritable Bowel Syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of antispasmodics, laxatives, dopamine antagonists, 5-HT3 antagonists and/or 5-HT4 agonists, opioid receptor agonist, antibacterial, chloride channel activators and guanylate cyclase-C agonist, which includes off label generic as well as marketed therapies) used for the management of IBS. Detailed chapter for upcoming therapies like BEKINDA (RedHill Biopharma) and Tenapanor (Ardelyx Inc) have been covered in the report.


Irritable Bowel Syndrome Market Outlook

The Irritable Bowel Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Irritable Bowel Syndrome in 7MM was found to be USD 1,380.6 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.


Irritable Bowel Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Irritable Bowel Syndrome Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Irritable Bowel Syndrome Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Irritable Bowel Syndrome Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Irritable Bowel Syndrome market

• Organize sales and marketing efforts by identifying the best opportunities for Irritable Bowel Syndrome market

• To understand the future market competition in the Irritable Bowel Syndrome market.

1. Key Insights

2. Irritable Bowel Syndrome (IBS) Market Overview at a Glance

2.1. Market Share (%) Distribution of IBS in 2017

2.2. Market Share (%) Distribution of IBS in 2028

3. Disease Background and Overview

3.1. Introduction

3.2. Cause

3.3. Signs and Symptoms

3.4. Pathophysiology of IBS

3.5. Diagnosis

3.6. Diagnostic Criteria

3.7. Differential Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

5. 7MM Total Prevalent Patient Population of Irritable Bowel Syndrome

6. Country Wise-Epidemiology of Irritable Bowel Syndrome

6.1. The United States

Assumptions and Rationale

6.1.1. Total Prevalent Cases of IBS in the United States

6.1.2. Diagnosed Prevalence of IBS by Types in the United States

6.1.3. Diagnosed Prevalence of IBS by Severity in the United States

6.1.4. Diagnosed Prevalence of IBS by Age Groups in the United States

6.1.5. Diagnosed Prevalence of IBS by Gender in the United States

6.2. EU5

Assumptions and Rationale

6.3. Germany

6.3.1. Total Prevalent Cases of IBS in Germany

6.3.2. Diagnosed Prevalence of IBS by Types in Germany

6.3.3. Diagnosed Prevalence of IBS by Severity in Germany

6.3.4. Diagnosed Prevalence of IBS by Age Groups in Germany

6.3.5. Diagnosed Prevalence of IBS by Gender in Germany

6.4. France

6.4.1. Total Prevalent Cases of IBS in France

6.4.2. Diagnosed Prevalence of IBS by Types in France

6.4.3. Diagnosed Prevalence of IBS by Severity in France

6.4.4. Diagnosed Prevalence of IBS by Age Groups in France

6.4.5. Diagnosed Prevalence of IBS by Gender in France

6.5. Italy

6.5.1. Total Prevalent Cases of IBS in Italy

6.5.2. Diagnosed Prevalence of IBS by Types in Italy

6.5.3. Diagnosed Prevalence of IBS by Severity in Italy

6.5.4. Diagnosed Prevalence of IBS by Age Groups in Italy

6.5.5. Diagnosed Prevalence of IBS by Gender in Italy

6.6. Spain

6.6.1. Total Prevalent Cases of IBS in Spain

6.6.2. Diagnosed Prevalence of IBS by Types in Spain

6.6.3. Diagnosed Prevalence of IBS by Severity in Spain

6.6.4. Diagnosed Prevalence of IBS by Age Groups in Spain

6.6.5. Diagnosed Prevalence of IBS by Gender in Spain

6.7. The United Kingdom

6.7.1. Total Prevalent Cases of IBS in the UK

6.7.2. Diagnosed Prevalence of IBS by Types in the UK

6.7.3. Diagnosed Prevalence of IBS by Severity in the UK

6.7.4. Diagnosed Prevalence of IBS by Age Groups in the UK

6.7.5. Diagnosed Prevalence of IBS by Gender in the UK

6.8. Japan

Assumptions and Rationale

6.8.1. Total Prevalent Cases of IBS in Japan

6.8.2. Diagnosed Prevalence of IBS by Types in Japan

6.8.3. Diagnosed Prevalence of IBS by Severity in Japan

6.8.4. Diagnosed Prevalence of IBS by Age Groups in Japan

6.8.5. Diagnosed Prevalence of IBS by Gender in Japan

7. Treatment and Management of Irritable Bowel Syndrome

7.1. Treatment Algorithm

7.1.1. Evaluation and Treatment of Suspected IBS by American Academy of Family Physicians

8. Unmet Needs

9. Marketed Drugs

9.1. BENTYL: Axcan Pharma Inc

9.1.1. Product Description

9.1.2. Regulatory Milestones

9.1.3. Safety and Efficacy

9.1.4. Product Profile

9.2. Xifaxan: Salix Pharmaceuticals, Inc.

9.2.1. Product Description

9.2.2. Regulatory Milestones

9.2.3. Safety and Efficacy

9.2.4. Product Profile

9.3. LOTRONEX: Prometheus Laboratories

9.3.1. Product Description

9.3.2. Regulatory Milestones

9.3.3. Other Developmental Activities

9.3.4. Safety and Efficacy

9.3.5. Product Profile

9.4. Amitiza: Takeda Pharmaceuticals

9.4.1. Product Description

9.4.2. Regulatory Milestones

9.4.3. Other Developmental Activities

9.4.4. Safety and Efficacy

9.4.5. Product Profile

9.5. LINZESS: Forest Pharmaceuticals, Inc.

9.5.1. Product Description

9.5.2. Regulatory Milestones

9.5.3. Other Developmental Activities

9.5.4. Safety and Efficacy

9.5.5. Product Profile

9.6. Ramosetron: Astellas Pharma

9.6.1. Product Description

9.6.2. Regulatory Milestones

9.6.3. Safety and Efficacy

9.6.4. Product Profile

9.7. Viberzi: Allergan plc

9.7.1. Product Description

9.7.2. Regulatory Milestones

9.7.3. Other Developmental Activities

9.7.4. Safety and Efficacy

9.7.5. Product Profile

9.8. Zelnorm: Novartis

9.8.1. Product Description

9.8.2. Regulatory Milestones

9.8.3. Safety and Efficacy

9.8.4. Product Profile

9.9. TRULANCE: Bausch Health

9.9.1. Product Description

9.9.2. Regulatory Milestones

9.9.3. Other Developmental Activities

9.9.4. Safety and Efficacy

9.9.5. Product Profile

9.10. Antidepressants

10. Emerging Drugs Analysis

11. Emerging Therapies

11.1. BEKINDA®: RedHill Biopharma

11.1.1. Product Description

11.1.2. Clinical Development

11.1.3. Safety and Efficacy

11.1.4. Product Profile

11.2. Tenapanor: Ardelyx Inc

11.2.1. Product Description

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Safety and Efficacy

11.2.5. Product Profile

12. Irritable Bowel Syndrome: 7 Major Market Analysis

12.1. Key Findings

12.2. Assumptions and Caveats

12.3. Market Size of Irritable Bowel Syndrome in 7MM

Market Size of Irritable Bowel Syndrome by Therapies

13. Market Outlook by Country

13.1. The United States: Market Outlook

13.2. United States Market Size

13.2.1. Total Market Size of Irritable Bowel Syndrome

13.2.2. Market Size of Irritable Bowel Syndrome by Therapies

14. EU-5 Countries: Market Outlook

14.1. Germany

14.1.1. Total Market size of Irritable Bowel Syndrome

14.1.2. Market Size of Irritable Bowel Syndrome by Therapies

14.2. France

14.2.1. Total Market Size of Irritable Bowel Syndrome

14.2.2. Market Size of Irritable Bowel Syndrome by Therapies

14.3. Italy

14.3.1. Total Market Size of Irritable Bowel Syndrome

14.3.2. Market Size of Irritable Bowel Syndrome by Therapies

14.4. Spain

14.4.1. Total Market Size of Irritable Bowel Syndrome

14.4.2. Market Size of Irritable Bowel Syndrome by Therapies

14.5. United Kingdom

14.5.1. Total Market Size of Irritable Bowel Syndrome

14.5.2. Market Size of Irritable Bowel Syndrome by Therapies

15. Japan: Market Outlook

15.1.1. Total Market Size of Irritable Bowel Syndrome

15.1.2. Market Size of Irritable Bowel Syndrome by Therapies

16. Market Drivers

17. Market Barriers

18. Appendix

18.1. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Table 1: Prevalent Patient Population of Irritable Bowel Syndrome in 7MM (2017-2028)

Table 2: Total Prevalent Cases of IBS in the United States (2017-2028)

Table 3: Diagnosed Prevalence of IBS by Types in the US (2017-2028)

Table 4: Diagnosed Prevalence of IBS by Severity in the United States (2017-2028)

Table 5: Diagnosed Prevalence of IBS by Age Groups in the United States (2017-2028)

Table 6: Diagnosed Prevalence of IBS by Gender in the United States (2017-2028)

Table 7: Total Prevalent Cases of IBS in Germany (2017-2028)

Table 8: Diagnosed Prevalence of IBS by Types in Germany (2017-2028)

Table 9: Diagnosed Prevalence of IBS by Severity in Germany (2017-2028)

Table 10: Diagnosed Prevalence of IBS by Age Groups in Germany (2017-2028)

Table 11: Diagnosed Prevalence of IBS by Gender in Germany (2017-2028)

Table 12: Total Prevalent Cases of IBS in France (2017-2028)

Table 13: Diagnosed Prevalence of IBS by Types in France (2017-2028)

Table 14: Diagnosed Prevalence of IBS by Severity in France (2017-2028)

Table 15: Diagnosed Prevalence of IBS by Age Groups in France (2017-2028)

Table 16: Diagnosed Prevalence of IBS by Gender in France (2017-2028)

Table 17: Total Prevalent Cases of IBS in Italy (2017-2028)

Table 18: Diagnosed Prevalence of IBS by Types in Italy (2017-2028)

Table 19: Diagnosed Prevalence of IBS by Severity in Italy (2017-2028)

Table 20: Diagnosed Prevalence of IBS by Age Groups in Italy (2017-2028)

Table 21: Diagnosed Prevalence of IBS by Gender in Italy (2017-2028)

Table 22: Total Prevalent Cases of IBS in Spain (2017-2028)

Table 23: Diagnosed Prevalence of IBS by Types in Spain (2017-2028)

Table 24: Diagnosed Prevalence of IBS by Severity in Spain (2017-2028)

Table 25: Diagnosed Prevalence of IBS by Age Groups in Spain (2017-2028)

Table 26: Diagnosed Prevalence of IBS by Gender in Spain (2017-2028)

Table 27: Total Prevalent Cases of IBS in the UK (2017-2028)

Table 28: Diagnosed Prevalence of IBS by Types in the UK (2017-2028)

Table 29: Diagnosed Prevalence of IBS by Severity in the UK (2017-2028)

Table 30: Diagnosed Prevalence of IBS by Age Groups in the UK (2017-2028)

Table 31: Diagnosed Prevalence of IBS by Gender in the UK (2017-2028)

Table 32: Total Prevalent Cases of IBS in Japan (2017-2028)

Table 33: Diagnosed Prevalence of IBS by Types in Japan (2017-2028)

Table 34: Diagnosed Prevalence of IBS by Severity in Japan (2017-2028)

Table 35: Diagnosed Prevalence of IBS by Age Groups in Japan (2017-2028)

Table 36: Diagnosed Prevalence of IBS by Gender in Japan (2017-2028)

Table 37: Comparison of Emerging drugs

Table 38: Gaboxadol, Clinical Trial Description, 2018

Table 39: Diazoxide Choline Controlled-Release Tablet (DCCR) Clinical Trial Description, 2019

Table 40: 7 Major Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 41: 7 Major Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Table 42: United States Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 43: The US Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Table 44: Germany Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 45: Germany Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Table 46: France Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 47: France Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Table 48: Italy Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 49: Italy Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Table 50: Spain Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 51: Spain Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Table 52: United Kingdom Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 53: The UK Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Table 54: Japan Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Table 55: Japan Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 1: Diagnostic and initial approach to the management of the patient with IBS-type symptoms

Figure 2: Rome III and Rome IV diagnostic criteria for IBS

Figure 3: Prevalent Patient Population of Irritable Bowel Syndrome in 7MM (2017-2028)

Figure 4: Total Prevalent Cases of IBS in the United States (2017-2028)

Figure 5: Diagnosed Prevalence of IBS by Types in the US (2017-2028)

Figure 6: Diagnosed Prevalence of IBS by Severity in the United States (2017-2028)

Figure 7: Diagnosed Prevalence of IBS by Age Groups in the United States (2017-2028)

Figure 8: Diagnosed Prevalence of IBS by Gender in the United States (2017-2028)

Figure 9: Total Prevalent Cases of IBS in Germany (2017-2028)

Figure 10: Diagnosed Prevalence of IBS by Types in Germany (2017-2028)

Figure 11: Diagnosed Prevalence of IBS by Severity in Germany (2017-2028)

Figure 12: Diagnosed Prevalence of IBS by Age Groups in Germany (2017-2028)

Figure 13: Diagnosed Prevalence of IBS by Gender in Germany (2017-2028)

Figure 14: Total Prevalent Cases of IBS in France (2017-2028)

Figure 15: Diagnosed Prevalence of IBS by Types in France (2017-2028)

Figure 16: Diagnosed Prevalence of IBS by Severity in France (2017-2028)

Figure 17: Diagnosed Prevalence of IBS by Age Groups in France (2017-2028)

Figure 18: Diagnosed Prevalence of IBS by Gender in France (2017-2028)

Figure 19: Total Prevalent Cases of IBS in Italy (2017-2028)

Figure 20: Diagnosed Prevalence of IBS by Types in Italy (2017-2028)

Figure 21: Diagnosed Prevalence of IBS by Severity in Italy (2017-2028)

Figure 22: Diagnosed Prevalence of IBS by Age Groups in Italy (2017-2028)

Figure 23: Diagnosed Prevalence of IBS by Gender in Italy (2017-2028)

Figure 24: Total Prevalent Cases of IBS in Spain (2017-2028)

Figure 25: Diagnosed Prevalence of IBS by Types in Spain (2017-2028)

Figure 26: Diagnosed Prevalence of IBS by Severity in Spain (2017-2028)

Figure 27: Diagnosed Prevalence of IBS by Age Groups in Spain (2017-2028)

Figure 28: Diagnosed Prevalence of IBS by Gender in Spain (2017-2028)

Figure 29: Total Prevalent Cases of IBS in the UK (2017-2028)

Figure 30: Diagnosed Prevalence of IBS by Types in the UK (2017-2028)

Figure 31: Diagnosed Prevalence of IBS by Severity in the UK (2017-2028)

Figure 32: Diagnosed Prevalence of IBS by Age Groups in the UK (2017-2028)

Figure 33: Diagnosed Prevalence of IBS by Gender in the UK (2017-2028)

Figure 34: Total Prevalent Cases of IBS in Japan (2017-2028)

Figure 35: Diagnosed Prevalence of IBS by Types in Japan (2017-2028)

Figure 36: Diagnosed Prevalence of IBS by Severity in Japan (2017-2028)

Figure 37: Diagnosed Prevalence of IBS by Age Groups in Japan (2017-2028)

Figure 38: Diagnosed Prevalence of IBS by Gender in Japan (2017-2028)

Figure 39: Management algorithm for irritable bowel syndrome

Figure 40: Algorithm for the evaluation and treatment of patients with suspected IBS

Figure 41: Unmet Needs of Irritable bowel syndrome

Figure 42: 7 Major Market Size of Irritable Bowel Syndrome in USD Million (2017-2028)

Figure 43: 7 Major Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 44: Market Size of Irritable Bowel Syndrome in the United States, USD Million (2017-2028)

Figure 45: The US Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 46: Market Size of Irritable Bowel Syndrome in Germany, USD Million (2017-2028)

Figure 47: Germany Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 48: Market Size of Irritable Bowel Syndrome in France USD Million (2017-2028)

Figure 49: France Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 50: Market Size of Irritable Bowel Syndrome in Italy, USD Million (2017-2028)

Figure 51: Italy Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 52: Market Size of Irritable Bowel Syndrome in Spain, USD Million (2017-2028)

Figure 53: Spain Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 54: Market Size of Irritable Bowel Syndrome in the United Kingdom, USD Million (2017-2028)

Figure 55: The UK Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 56: Market Size of Irritable Bowel Syndrome in Japan, USD Million (2017-2028)

Figure 57: Japan Market Size of Irritable Bowel Syndrome by Therapies in USD Million (2017-2028)

Figure 58: Market Drivers

Figure 59: Market Barriers

  • Tags:
  • Irritable Bowel Syndrome (IBS) mar...
  • Irritable Bowel Syndrome (IBS) mar...
  • Irritable Bowel Syndrome (IBS) mar...
  • Irritable Bowel Syndrome (IBS) mar...
  • Irritable Bowel Syndrome (IBS) mar...
  • Irritable Bowel Syndrome (IBS) mar...
  • Irritable Bowel Syndrome (IBS) pip...
  • Irritable Bowel Syndrome (IBS) tre...
  • Irritable Bowel Syndrome (IBS) dru...
  • Irritable Bowel Syndrome (IBS) sal...
  • Irritable Bowel Syndrome (IBS) mar...
  • Irritable Bowel Syndrome (IBS) dis...
  • Irritable Bowel Syndrome (IBS) epi...
  • Irritable Bowel Syndrome (IBS)
  • Irritable Bowel Syndrome (IBS) Com...
  • Irritable Bowel Syndrome (IBS) Pi...

Forward to Friend

Need A Quote